Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Dec 22;375(25):2504-2505.
doi: 10.1056/NEJMc1610047.

Interim Buprenorphine vs. Waiting List for Opioid Dependence

Stacey C Sigmon  1 , Taylor A Ochalek  1 , Andrew C Meyer  1 , Bryce Hruska  1 , Sarah H Heil  1 , Gary J Badger  1 , Gail Rose  1 , John R Brooklyn  1 , Robert P Schwartz  2 , Brent A Moore  3 , Stephen T Higgins  4
Affiliations
Randomized Controlled Trial

Interim Buprenorphine vs. Waiting List for Opioid Dependence

Stacey C Sigmon et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Abstinence from Illicit Opioids and Intravenous Opioids over 12 Weeks with Interim Buprenorphine
Panel A shows the effects of interim buprenorphine on abstinence from illicit opioid use over 12 weeks. Data points represent the percentage of participants who submitted urine specimens with negative results for illicit opioids at intake and at assessments every 4 weeks thereafter. Panel B shows the effects of interim buprenorphine on the self-reported frequency of the use of illicit opioids, and Panel C shows the effects of interim buprenorphine on the use of intravenous opioids. The y axis for intravenous opioid use is presented on a smaller scale to allow for more detailed inspection of the data. Asterisks represent observations at assessments at 4, 8, and 12 weeks that were significantly different between groups (P<0.001). T bars represent standard errors.
See this image and copyright information in PMC

Comment in

References

    1. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309:657–9. - PubMed
    1. Peles E, Schreiber S, Adelson M. Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry. J Addict Med. 2013;7:177–82. - PubMed
    1. Sigmon SC, C Meyer A, Hruska B, et al. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility. Addict Behav. 2015;51:136–42. - PMC - PubMed
    1. McLellan AT, Luborsky L, Cacciola J, et al. New data from the Addiction Severity Index: reliability and validity in three centers. J Nerv Ment Dis. 1985;173:412–23. - PubMed
    1. Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf. 2008;17:997–1005. - PubMed